Clinical trial results

Trial Results

A plain-English summary of what published Huntington's disease clinical trial results actually show. It is based only on outcomes reported in the trial registries Fenix tracks — not on news, announcements or opinion.

Results announced — not yet independently verified

These results were announced by the trial sponsor, but have not yet been independently verified by Fenix through a peer-reviewed publication or trial-registry results record. They are therefore not included in the verified results summary below.

  • AMT-130 (uniQure)

    Sponsor announcement
    Not independently verified

    Sponsor-reported topline results

    Announced 24 September 2025

    uniQure announced topline results from its ongoing gene therapy programme for Huntington's disease, reporting that people who received the higher dose of AMT-130 declined more slowly than an external comparison group after three years. The company also reported that the therapy was generally well tolerated. These figures come from the company itself and have not yet been published in a peer-reviewed journal or posted to a trial registry, so Fenix has not been able to check them independently.

    Read the uniQure company announcement

Other studies

AI-generated summary
What recent Huntington's trials have actually shown

Some recent drug trials for Huntington's disease have shown statistically significant changes on the specific tests they measured. A few studies reduced involuntary movements (chorea) on standard movement scores. Other trials reported changes in laboratory measures such as huntingtin protein in blood or spinal fluid. Laboratory (biomarker) changes are not the same as people feeling or functioning better.

Key results

  • Positive finding
    Treatment for symptoms

    In the KINECT‑HD trial, valbenazine reduced involuntary movements as measured by the Total Maximal Chorea score (TMC) of the Unified Huntington's Disease Rating Scale (UHDRS).

    Main measure of the trial

    Reported figures: p < 0.0001; average change -4.60 vs -1.44 points on the TMC.

  • Positive finding
    Treatment for symptoms

    In First‑HD, deutetrabenazine reduced involuntary movements on the same involuntary movements score (Total Maximal Chorea, TMC of the Unified Huntington's Disease Rating Scale).

    Main measure of the trial

    Reported figures: p < 0.0001; average change -4.42 vs -1.93 points on the TMC.

  • Mixed finding
    Treatment for symptoms

    In a randomized phase 2b study of SOM3355 (in participants who were not taking neuroleptics), the Total Maximal Chorea score (TMC) fell from baseline to the end of maintenance dosing and this primary result reached statistical significance.

    Only in part of the participants

    Reported figures: p = 0.045; reported mean changes included -2.19 points (and -2.42 and -3.46 points in other dose groups reported).

  • Inconclusive
    Laboratory measure only

    PTC518 produced statistically significant reductions in the total huntingtin protein measured in blood at Month 3 (a laboratory measure of the huntingtin protein that causes Huntington's disease).

    Laboratory measure, not symptoms

    Reported figures: p < 0.0001; percent changes at Month 3 reported as about -1.4%, -17.36%, and -28.67% across dose groups.

  • Mixed finding
    Treatment for symptoms

    SAGE‑718 did not meet its primary measure: change on the Symbol Digit Modalities Test (SDMT) at Day 84 was not statistically significant; however, an additional measure of everyday functioning at home (Huntington's Disease Everyday Functioning, Hi‑DEF home subdomain) did show a statistically significant difference.

    Additional measure only — main measure not confirmed

    Reported figures: SDMT primary p = 0.1675 (change 2.0 vs 0.8); Hi‑DEF home subdomain p = 0.0291 (change -4.6 vs -0.7). The trial's main measure did not reach significance, so the positive secondary result must be interpreted cautiously.

  • Negative finding
    Treatment for symptoms

    In PROOF‑HD, pridopidine did not show a statistically significant difference in the trial's main measure of overall day‑to‑day function (Total Functional Capacity score of the Unified Huntington's Disease Rating Scale) at Week 65.

    Main measure of the trial

    Reported figures: mITT primary p = 0.1670 (mean change -1.18 vs -0.95); ITT p = 0.1598 (mean change -1.17 vs -0.94).

What a "statistically significant" result means

A statistically significant change on a test does not automatically mean people feel better or that the disease is slowed. Changes in laboratory measures (biomarkers) are not proof that symptoms or daily life improved.

What the evidence cannot yet tell us

  • Many registry entries list numeric changes without p‑values, so statistical significance cannot be judged from those records alone.
  • Changes in biomarkers (blood or cerebrospinal fluid huntingtin, imaging or brain‑wave measures) do not by themselves prove clinical benefit for symptoms or disease progression.
  • Trial completion or reported recruitment does not mean a treatment worked; only a trial's stated main measure with appropriate statistics can show that.
How was this summary created?

View the clinical trial results and sources used to generate this summary.

Based on 112 evidence records · Updated 22 Nov 2026

Last updated: 22 November 2026 at 03:34

This summary is generated from publicly available clinical trial results and is intended to help explain trial results in plain English. It is not medical advice.